Clinical Trial Details


Research Study Summary

Treatment of Nocturia or Frequent Nighttime Urination


Phase III Randomized, Double-Blind, Placebo Control, Multicenter Study to Investigate the Efficacy and Safety of SER 120 Nasal Spray Formulation in Patients with Nocturia

Patient Inclusion Criteria:

  • Men and women 50 years of age or older
  • Nocturia 2 or more times per night
  • Normal triglyceride levels

Patient Exclusion Criteria:

  • Incontinence
  • Diabetes
  • Congestive Heart Failure
  • Uncontrolled hypertension
  • History of bladder surgery or radiotherapy
  • Systemic steroids
  • Urological malignancies or unexplained pelvic masses
  • Current urinary tract infection
  • Bladder stones, bladder pain syndrome, interstitial cystitis
  • Obstructive sleep apnea
  • Restless leg syndrome
  • Substance abuse
  • Blood donation within 90 days
  • Smoking
  • Hepatitis, HIV
  • Investigational drug within 30 days
  • Allergic rhinitis or use of intra-nasal medication

To Learn more

CW ID: 156462
Date Last Changed: July 24, 2013

Clinical Trial Snapshot

Both Male and Female
50 and up
Overall Status
Facility Type


West Coast Clinical Research
5525 Etiwanda Ave., Suite 202
Tarzana, CA 91356
Phone: 818-776-0820, Ext. 101
Fax: 818-776-1269

View Map

Research Center Information:

West Coast Clinical Research

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.